Peter Gilbert and SCHARP researchers, HVTN Laboratory Program, part of worldwide effort to understand trial outcome, influence future HIV vaccine studies
April 9, 2012
Fred Hutchinson Cancer Research Center researchers played a key role in the discovery of important immune responses that may have protected some volunteers from HIV in the RV144 Thai trial, the first HIV vaccine trial to show modest effectiveness in preventing HIV infection. Results from extensive RV144 laboratory studies were published April 5 in the New England Journal of Medicine.
Science magazine selected HIV prevention trial for its top honor of 2011; study showed early antiretroviral therapy reduced heterosexual HIV transmission by 96 percent
Jan. 9, 2012
| By Colleen Steelquist and Dean Forbes
The Hutchinson Center's Statistical Center for HIV/AIDS Research & Prevention (SCHARP) played a key role in the HIV prevention study that Science magazine recently chose as its scientific breakthrough of the year for 2011.
Supported by SCHARP’s data management, HIV Prevention Trials Network shows 96 percent reduction in HIV transmission to uninfected sexual partners
May 23, 2011
Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by starting oral antiretroviral therapy, according to findings from a large multinational clinical study conducted by the HIV Prevention Trials Network, a global partnership dedicated to reducing the transmission of HIV through biomedical, behavioral, and structural interventions.
VIDI’s Elizabeth Brown studies mother-to-child transmission of HIV and more to make a difference in peoples’ lives
June 22, 2009
| By Rachel Tompa
From mother-to-child transmission of HIV to coronary artery lesions, Dr. Elizabeth Brown of the Fred Hutchinson Cancer Research Center loves a statistical challenge. And the more uncertain, the better—that’s where she believes good statistics can really make a difference.